Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHEA biomarker study of PF-03084014 in chemoresistant triple-negative breast cancer
2014-004358-32Phase 2Terminated
- Sponsor
- Institut Jules Bordet
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nirogacestat in triple-negative breast cancer (TNBC), sponsored by Institut Jules Bordet. Primary endpoint: Change in tumor HES4 gene expression. Started Mar 2015; status: terminated.
02
Drugs
nirogacestat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2014-004358-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004358-32.